Repare Therapeutics Stock Performance
| RPTX Stock | USD 1.51 0.01 0.66% |
On a scale of 0 to 100, Repare Therapeutics holds a performance score of 9. The company holds a Beta of 1.35, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Repare Therapeutics will likely underperform. Please check Repare Therapeutics' expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to make a quick decision on whether Repare Therapeutics' historical price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Repare Therapeutics are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain basic indicators, Repare Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 111.3 M | |
| Total Cashflows From Investing Activities | 49.5 M |
Repare Therapeutics Relative Risk vs. Return Landscape
If you would invest 120.00 in Repare Therapeutics on April 21, 2025 and sell it today you would earn a total of 31.00 from holding Repare Therapeutics or generate 25.83% return on investment over 90 days. Repare Therapeutics is currently generating 0.4356% in daily expected returns and assumes 3.8034% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Repare, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Repare Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Repare Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Repare Therapeutics, and traders can use it to determine the average amount a Repare Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1145
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | RPTX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.8 actual daily | 34 66% of assets are more volatile |
Expected Return
| 0.44 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 9 91% of assets perform better |
Based on monthly moving average Repare Therapeutics is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Repare Therapeutics by adding it to a well-diversified portfolio.
Repare Therapeutics Fundamentals Growth
Repare Stock prices reflect investors' perceptions of the future prospects and financial health of Repare Therapeutics, and Repare Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Repare Stock performance.
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.4 | ||||
| Operating Margin | (121.98) % | ||||
| Current Valuation | (55.52 M) | ||||
| Shares Outstanding | 42.89 M | ||||
| Price To Book | 0.49 X | ||||
| Price To Sales | 60.36 X | ||||
| Revenue | 53.48 M | ||||
| EBITDA | (93.52 M) | ||||
| Cash And Equivalents | 282.09 M | ||||
| Cash Per Share | 6.73 X | ||||
| Total Debt | 1.93 M | ||||
| Debt To Equity | 0.03 % | ||||
| Book Value Per Share | 2.92 X | ||||
| Cash Flow From Operations | (76.44 M) | ||||
| Earnings Per Share | (3.02) X | ||||
| Total Asset | 176.51 M | ||||
| Retained Earnings | (417.8 M) | ||||
About Repare Therapeutics Performance
Evaluating Repare Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Repare Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Repare Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company was incorporated in 2016 and is headquartered in Montreal, Canada. Repare Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 163 people.Things to note about Repare Therapeutics performance evaluation
Checking the ongoing alerts about Repare Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Repare Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Repare Therapeutics may become a speculative penny stock | |
| Repare Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 53.48 M. Net Loss for the year was (84.69 M) with profit before overhead, payroll, taxes, and interest of 395 K. | |
| Repare Therapeutics currently holds about 282.09 M in cash with (76.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.73, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 69.0% of the company shares are owned by institutional investors |
- Analyzing Repare Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Repare Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Repare Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Repare Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Repare Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Repare Therapeutics' stock. These opinions can provide insight into Repare Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Repare Stock Analysis
When running Repare Therapeutics' price analysis, check to measure Repare Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repare Therapeutics is operating at the current time. Most of Repare Therapeutics' value examination focuses on studying past and present price action to predict the probability of Repare Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repare Therapeutics' price. Additionally, you may evaluate how the addition of Repare Therapeutics to your portfolios can decrease your overall portfolio volatility.